Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Humacyte, Inc.NASDAQ: HUMA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $7.93M fell 2.5% year over year, ahead of the -10.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 36.1% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • Selling, general & admin amounted to 1529.5% of revenue in FY2025.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $39.18M (+25.7%) for the fiscal year ending Dec 2026, a step up from the +20.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.93M+36.1% QoQ
Last fiscal yearDec 2025
$31.17M+20.8% YoY
LTMMar 2026
$27.31M-10.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%+29.6%+32.1 pp
1 year+20.8%+25.7%+4.9 pp
3-year CAGR+10.9%+229.7%+218.9 pp
5-year CAGR+152.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
31.17M USD
Year-over-year change
+20.8%
4-year CAGR
+10.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 selling, general & admin of $27.31M is the 8th highest of the 11 companies compared; the peer median is $34.68M.
  • Its year-over-year change of -10.2% is the 9th highest of 11, against a peer median of +3.3%.
  • Selling, general & admin amounts to 1354.8% of revenue for HUMA, versus a peer median of 99.1%.
HUMA Competitors Peer median
Selling, General & Admin for HUMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B +29505.3%+3.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M +54.0%+20.4%117.7%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M -11.6%+0.0%96.1%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M +4.0%+10.2%712.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.17M -2.1%+6.6%99.1%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M +76.0%+43.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
HUMAHumacyte, Inc.LTM Mar 2026$27.31M -10.2%+10.9%1354.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$26.89M -3.6%-3.6%95.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$23.69M +2.7%+2.7%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$18.03M +5.9%+42.7%—
Peer median (excluding HUMA) $34.68M+3.3%+5.1%99.1%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.26M1.57M002.04M
Cost of Revenue61.34M8.26M76.55M7.19M17.05M
Gross Profit(60.08M)(6.69M)(76.55M)(7.19M)(15.01M)
Gross Margin-4756.8%-427.5%——-736.5%
Research & Development61.34M63.26M76.55M88.6M69.3M
Selling, General & Admin21.13M22.88M20.39M25.8M31.17M
Operating Expenses21.13M77.89M23.5M107.21M92.43M
Depreciation & Amortization8.24M8.21M7.72M7.19M7.35M
EBITDA(13.89M)2.45M(96.46M)(132.23M)(22.24M)
EBITDA Margin-1099.6%156.2%——-1091.2%
Operating Income(81.21M)(84.58M)(100.05M)(114.4M)(107.44M)
Operating Margin-6429.8%-5404.3%——-5271.7%
Interest Income16K2.63M5.47M4.1M2.59M
Interest Expense4.35M6.2M6.6M9.28M11.25M
Other Income / Expenses54.73M72.61M(10.73M)(34.3M)66.6M
Income Before Tax(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Pre-Tax Margin-2096.4%-764.5%——-2003.6%
Income Tax Expense00000
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Net Margin-2096.4%-764.5%——-2003.6%
EPS (Basic)(0.66)(0.12)(1.07)(1.26)(0.26)
EPS (Diluted)(0.66)(0.12)(1.07)(1.26)(0.26)
Weighted Avg Shares39.97M103.05M103.42M118.48M158.16M
Weighted Avg Shares (Diluted)39.97M103.05M103.42M118.48M158.16M

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.